Compare Amylx Pharmaceuticals Inc (AMLX) vs Invesco DB Oil Fund (DBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Invesco DB Oil Fund — how do they compare? Amylx Pharmaceuticals Inc trades at $23.99 (market cap $2.64B), while Invesco DB Oil Fund trades at $20.95. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Invesco DB Oil Fund nearer its low. Which is the better fit depends on your goals.
| AMLX | DBO | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Commodities - Energy |
52-Week High | $24.19 | $23.80 |
52-Week Low | $7.82 | $11.98 |
Enterprise Value | $2.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
DBO trades at $20.88, up 0.14% today, with a bullish technical signal driven by moving averages and neutral oscillators. Recent news highlights oil market volatility due to Middle East supply disruptions and OPEC demand forecast cuts. The stock lacks disclosed financial ratios, limiting fundamental clarity amid sector-wide data reliability concerns.
Outlook hinges on oil price stability and company-specific updates, with upside potential from supply shocks but risks from demand weakness and geopolitical uncertainty. Investors await earnings and guidance for valuation anchors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →
